AnaptysBio’s (ANAB) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Wednesday,RTT News reports. The firm currently has a $40.00 price target on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $19.00 price objective on shares of AnaptysBio in a report on Tuesday, February 4th. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Wolfe Research started coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $40.08.

AnaptysBio Stock Performance

ANAB stock opened at $16.15 on Wednesday. The business has a 50-day simple moving average of $16.06 and a two-hundred day simple moving average of $25.98. The company has a market capitalization of $491.44 million and a P/E ratio of -2.66. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now directly owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several hedge funds and other institutional investors have recently modified their holdings of ANAB. FMR LLC grew its stake in AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares in the last quarter. Jennison Associates LLC bought a new position in shares of AnaptysBio in the third quarter worth $8,874,000. Victory Capital Management Inc. boosted its holdings in shares of AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the period. Assenagon Asset Management S.A. grew its position in shares of AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of AnaptysBio during the 3rd quarter valued at $5,494,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.